| Literature DB >> 29518063 |
Igor V Ukrainets1, Ganna M Hamza2, Anna A Burian3, Svitlana V Shishkina4,5, Natali I Voloshchuk6, Oxana V Malchenko7.
Abstract
In order to determine the regularities of the structure-analgesic activity relationship, the peculiarities of obtaining, the spatial structure, and biological properties of 4-methyl-2,2-dioxo-1H-2λ⁶,Entities:
Keywords: 2,1-benzothiazine; 4-methyl-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxylic acid; analgesic activity; anti-inflammatory action; crystal structure; esters; hydrolysis
Year: 2018 PMID: 29518063 PMCID: PMC5874539 DOI: 10.3390/scipharm86010009
Source DB: PubMed Journal: Sci Pharm ISSN: 0036-8709
Figure 1Analgesic-acids that are officially registered drugs [1,2].
Figure 2Probable (IX) and known (XI and XIII) hydrolysis products of esters of 4-hydroxy-2-oxoquinoline- [7] and 4-hydroxy-2,2-dioxo-2,1-benzothiazine- [8] 3-carboxylic acids.
Scheme 1The peculiarities of 4-methyl-2,2-dioxo-1H-2λ6,1-benzothiazine-3-carboxylic acid (5) preparation.
Figure 3The standard representation of different atoms in different colors. The molecular structure of sodium salt monohydrate 3 with atoms represented by thermal vibration ellipsoids of 50% probability.
Figure 4Packing of Sodium salt monohydrate 3 in the crystal phase. Projection along [1 0 0] crystallographic direction.
Figure 5The molecular structure of acid monohydrate 4 with atoms represented by thermal vibration ellipsoids of 50% probability.
Figure 6Packing of acid monohydrate 4 in the crystal phase. Projection along [0 1 0] crystallographic direction.
Figure 7Derivatograms of acid monohydrate 4: thermogravimetric curve (black); differential thermogravimetric curve (blue). Sample weight 7.57 mg.
Figure 8The molecular structure of benzothiazine 7 with atoms represented by thermal vibration ellipsoids of 50% probability.
Figure 9The chain of benzothiazine 7 molecules bound by hydrogen bonds.
The Anti-Inflammatory Activity of Sodium Salt 3, Acid 4, and Reference Drugs.
| Entry | Product | R | Volume of Damaged Extremity (mm3) | Volume of Non-Damaged Extremity (mm3) | ΔVolume (Volume Increase) | Anti- Inflammatory Activity, Compared to Control (%) |
|---|---|---|---|---|---|---|
| 1 | Na | 516.3 ± 15.8 | 304.9 ± 14.0 | 211.4 ± 16.5 1,2,3 | 48.9 | |
| 2 | H | 568.6 ± 16.5 | 268.7 ± 7.59 | 299.9 ± 20.1 1,2,3 | 27.5 | |
| 3 | Lornoxicam | – | 360.5 ± 26.4 | 263.9 ± 19.8 | 96.58 ± 7.62 1 | 76.7 |
| 4 | Diclofenac | – | 397.6 ± 11.9 | 306.6 ± 9.36 | 91.05 ± 5.52 1 | 78.0 |
| 5 | Control | – | 768.7 ± 27.3 | 354.9 ± 11.6 | 413.7 ± 32.2 | 0 |
1 Differences statistically significant for p ≤ 0.05 vs. control. 2 Differences statistically significant for p ≤ 0.05 vs. Diclofenac. 3 Differences statistically significant for p ≤ 0.05 vs. Lornoxicam.
The Analgesic Activity of Sodium Salt 3, Acid 4, and Reference Drugs.
| Entry | Product | R | Pain Threshold on Damaged Extremity (g/mm2) | Pain Threshold on Non-Damaged Extremity (g/mm2) | ΔPain Threshold | Analgesic Activity, Compared to Control (%) |
|---|---|---|---|---|---|---|
| 1 | Na | 350.0 ± 15.8 | 306.0 ± 19.6 | 44.0 ± 8.12 1,3 | 86.2 | |
| 2 | H | 294.0 ± 32.3 | 208.0 ± 17.7 | 86.0 ± 18.6 1 | 73.0 | |
| 3 | Lornoxicam | – | 441.0 ± 25.6 | 346.0 ± 23.4 | 95.0 ± 4.47 1,2 | 70.1 |
| 4 | Diclofenac | – | 738.0 ± 18.3 | 679.0 ± 25.4 | 59.0 ± 9.27 1 | 81.4 |
| 5 | Control | – | 593.0 ± 56.3 | 275.0 ± 32.1 | 318.0 ± 34.9 | 0 |
1 Differences statistically significant for p ≤ 0.05 vs. control. 2 Differences statistically significant for p ≤ 0.05 vs. Diclofenac. 3 Differences statistically significant for p ≤ 0.05 vs. Lornoxicam.